CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 

Cumulative Fibrogen Inc 's Working Capital Ratio for Trailing Twelve Months Period

FGEN's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

FGEN Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -16.9 % -19.25 % -0.25 % 21.32 % 20.39 %
Y / Y Current Assets Growth -23.22 % -20.99 % -17.9 % 3.96 % -17.3 %
Working Capital Ratio for Trailing Twelve Months Period 1.82 1.86 1.88 1.97 2.05
Total Ranking # 1987 # 2073 # 2275 # 2410 # 2299
Seq. Current Liabilities Growth 7.91 % -23.82 % -6.88 % 8.56 % 4.85 %
Seq. Current Assets Growth -11.49 % -4.46 % -12.64 % 3.92 % -8.92 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Fibrogen Inc 's average Current Liabilities to $209 millions, Working Capital Ratio for Trailing Twelve Months Period to 1.82 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 403 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Fibrogen Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about FGEN
Working Capital Ratio FGEN in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 404
Sector # 785
S&P 500 # 2073


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.16 5.5 1.82
(Jun 30 2018)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Galecto Inc   5.01 
Merus N v   4.99 
Proqr Therapeutics N v   4.98 
Puretech Health Plc  4.95 
Qilian International Holding Group Limited  4.92 
Iterum Therapeutics Plc  4.92 
Edesa Biotech Inc   4.91 
Kiniksa Pharmaceuticals Ltd   4.91 
Seres Therapeutics Inc   4.90 
Coya Therapeutics Inc   4.87 
Monopar Therapeutics Inc   4.87 
Bionomics Limited  4.87 
Frequency Therapeutics Inc   4.85 
Catalyst Pharmaceuticals Inc   4.85 
Bridgebio Pharma Inc   4.84 
Trevena inc   4.83 
Geovax Labs Inc   4.82 
Cervomed Inc   4.81 
Vincerx Pharma Inc   4.79 
Zymeworks Inc   4.79 
Galmed Pharmaceuticals Ltd   4.78 
Unity Biotechnology Inc   4.78 
Renovorx Inc   4.78 
Karyopharm Therapeutics Inc   4.76 
Atreca inc   4.73 
Mirum Pharmaceuticals Inc   4.73 
Purple Biotech Ltd   4.71 
Abeona Therapeutics Inc   4.71 
Macrogenics Inc   4.69 
Virpax Pharmaceuticals Inc   4.67 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com